8:30 AM ET
8-K
Other 8-K Filing
Immunome Other 8-K Filing
Immunome entered into an amendment with Bristol-Myers Squibb (BMS) to eliminate all future milestone and royalty payment obligations related to varegacestat and AL101. In exchange, Immunome paid BMS $20 million in cash and issued approximately 4.4 million shares of common stock, while also gaining full ownership of the related patent rights.
- Counterparty
- Bristol-Myers Squibb Company